ASX:MYX Mayne Pharma Group (MYX) Stock Price, News & Analysis → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free MYX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume5.47 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield0.84%Price TargetN/A Stock AnalysisStock Analysis Get Mayne Pharma Group alerts: Email Address Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Mayne Pharma Group Stock (ASX:MYX)Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.Read More Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. MYX Stock News HeadlinesApril 21, 2024 | finance.yahoo.comFavourable Signals For Mayne Pharma Group: Numerous Insiders Acquired StockMarch 31, 2024 | finance.yahoo.comInvestors in Mayne Pharma Group (ASX:MYX) have seen respectable returns of 93% over the past yearMay 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.February 21, 2024 | investing.comMayne Pharma Group Ltd (MYX)February 15, 2024 | uk.finance.yahoo.comMithra sells shares in Mayne PharmaFebruary 15, 2024 | finanznachrichten.deMithra Pharmaceuticals: Mithra sells shares in Mayne PharmaFebruary 15, 2024 | wsj.comMayne Pharma Group Ltd.December 2, 2023 | morningstar.comMayne Pharma Group Ltd MYXMay 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.September 27, 2023 | finance.yahoo.comHow much Novan sold its assets for in bankruptcy caseSeptember 11, 2023 | uk.finance.yahoo.comMayne Pharma Group Limited (HG6.F)August 31, 2023 | fool.com.auGuess which ASX 300 healthcare stock just tanked 20%June 8, 2023 | msn.comWILSONS Upgrades Mayne Pharma Group (ASX:MYX)June 8, 2023 | finance.yahoo.comRetail investors account for 50% of Mayne Pharma Group Limited's (ASX:MYX) ownership, while institutions account for 19%June 1, 2023 | msn.comMayne Pharma Group (ASX:MYX) Price Target Increased by 7.69% to 4.43May 15, 2023 | finance.yahoo.comMayne Pharma Group (ASX:MYX shareholders incur further losses as stock declines 13% this week, taking five-year losses to 72%March 30, 2023 | msn.comMultiple directors are buying this beaten-up ASX 300 healthcare stockMarch 28, 2023 | finance.yahoo.comFrank Condella Is The Independent Non-Executive Chairman of Mayne Pharma Group Limited (ASX:MYX) And They Just Picked Up 56% More SharesMarch 1, 2023 | finanznachrichten.deDr. Reddy's Laboratories Ltd.: Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product PortfolioMarch 1, 2023 | seekingalpha.comDr. Reddy's to acquire U.S. generic portfolio of Mayne PharmaMarch 1, 2023 | msn.comGuess which ASX 300 share has rocketed 27% in 2 days since reportingJanuary 16, 2023 | fool.com.auCRASH! Why Mayne Pharma Group Ltd’s share price plunged 22% todayJanuary 2, 2023 | fool.com.auIs the Mayne Pharma Group Ltd share price too cheap to ignore?December 29, 2022 | finance.yahoo.comMayne Pharma Group Limited (ASX:MYX) most popular amongst individual investors who own 56% of the shares, institutions hold 20%November 30, 2022 | fool.com.auWhy is this ASX All Ords share crashing 27% today?August 21, 2022 | fool.com.auMayne Pharma Group Ltd doubles sales: Is it a buy?August 10, 2022 | fool.com.auMayne Pharma share price rockets 25% on $680 million paydaySee More Headlines Receive MYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2019Today5/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolASX:MYX CUSIPN/A CIKN/A Webwww.maynepharma.com Phone+61-8-82092666FaxN/AEmployees780Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.51Net Income$-274,180,000.00 Net Margins-76.21% Pretax MarginN/A Return on Equity-40.74% Return on Assets-5.46% Debt Debt-to-Equity Ratio6.68 Current Ratio1.61 Quick Ratio0.62 Sales & Book Value Annual Sales$319.28 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.20 Book ValueA$6.74 per share Price / BookN/AMiscellaneous Outstanding Shares85,070,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.32 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Shawn Patrick O'Brien B.Sc (Age 65)CEO, MD & Director Comp: $1.27MMr. Aaron GrayChief Financial OfficerMs. Kimberly Parker J.D.Executive VP & General CounselMr. Brant Schofield (Age 58)Executive Vice President of Corporate Development Comp: $1.04MMs. Erinn NathanielDirector of Global Human ResourcesMr. Daniel MooreExecutive Vice President of CommercialDr. Frank Casty M.D.Executive VP & Global Chief Medical OfficerMr. Brenton WalterFinancial ControllerMs. Laura LoftusAssociate General Counsel & Company SecretaryMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFView All CompetitorsInsidersShawn O'BrienSold 290,554 sharesTotal: $1.70 M ($5.85/share)Frank CondellaBought 7,154 shares on 12/1/2023Total: $38,810.45 ($5.43/share)Kathryn MacFarlaneBought 18,000 shares on 10/25/2023Total: $69,120.00 ($3.84/share)Ann CustinBought 6,037 shares on 10/23/2023Total: $20,205.84 ($3.35/share)Ann CustinBought 6,250 shares on 10/20/2023Total: $20,918.75 ($3.35/share) MYX Stock Analysis - Frequently Asked Questions How were Mayne Pharma Group's earnings last quarter? Mayne Pharma Group Limited (ASX:MYX) released its earnings results on Friday, February, 22nd. The company reported $0.02 earnings per share for the quarter. Mayne Pharma Group had a negative trailing twelve-month return on equity of 40.74% and a negative net margin of 76.21%. Is Mayne Pharma Group a good dividend stock? Mayne Pharma Group (ASX:MYX) pays an annual dividend of A$0.04 per share and currently has a dividend yield of 0.84%. What other stocks do shareholders of Mayne Pharma Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mayne Pharma Group investors own include Sundance Energy (SNDE), Turquoise Hill Resources (TRQ), Telstra Group (TLS), Green Organic Dutchman (TGODF), Perseus Mining (PRU), Organigram (OGI), Karoon Energy (KAR), Crown Resorts (CWN) and Cronos Group (CRON). This page (ASX:MYX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mayne Pharma Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
